Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.